pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Oncology · news · pharmadog
← back to Oncology
News · Oncology
1,499
stories
Aug 5, 26
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
Aug 5, 26
Fresenius Kabi Issues Voluntary Nationwide Recall of One Lot of Morphine Sulfate Injection, USP in a Simplist® Prefilled Syringe Due to Labeling Mix-up
fda medwatch
Aug 4, 26
Pfizer CEO defends $7B bolt-on M&A strategy as peers rush to buy
biospace
Aug 4, 26
Merck plans trial of sac-TMT combo with Keytruda in lung cancer
endpoints
Aug 4, 26
Pfizer expands multibillion-dollar cost-cutting plan
biopharma dive
Aug 4, 26
Merck’s $10.8B Prometheus deal delivers another win—plus a Phase 2b miss
biospace
Aug 4, 26
BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine
biospace
Aug 4, 26
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
Aug 4, 26
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
Aug 4, 26
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
biospace
Aug 4, 26
Lisata lays off 72% of staffers, sues Kuva after planned merger falls apart
fiercebiotech
Aug 4, 26
Pfizer axes ex-Metsera obesity asset and GIPR prospect in quarterly clearout
fiercebiotech
Aug 4, 26
Opinion: How Josée became one of the 7.9% of Québécois who die by assisted suicide
stat
Aug 4, 26
Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx
fiercebiotech
Aug 4, 26
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
Aug 4, 26
Recon: Lilly to broaden expanded access for unapproved obesity drug; Jazz to withdraw second-line SCLC indication for Zepzelca
raps
Aug 3, 26
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
Aug 3, 26
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
Aug 3, 26
FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients
endpoints
Aug 3, 26
Curium strikes up to $8B deal for radiopharma rival Lantheus
fiercebiotech
Aug 3, 26
BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotech
biospace
Aug 3, 26
STAT+: BioNTech names Guido Oelkers its new CEO
stat
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Aug 3, 26
BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
fiercebiotech
Aug 3, 26
After 5-month wait, BioNTech announces Sobi CEO will take on top job at mRNA company
fiercebiotech
Aug 3, 26
Biotech leaders call for streamlining of INDs as FDA’s Trialblazer rolls out
biospace
Aug 3, 26
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
Jul 31, 26
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
Jul 31, 26
UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma
biospace
Jul 31, 26
Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer
endpoints
← prev
page 26 of 50
next →
